Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Trastuzumab Deruxtecan in Solid Tumors with HER2 Activating Mutations
2024-516158-22-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Jul 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab deruxtecan in solid neoplasms, cancer and Metastatic solid neoplasm, sponsored by AstraZeneca. Primary endpoint: Confirmed objective response rate by RECIST v1.1 based on independent central review. Planned start Jul 2024; status: authorised.
02
Drugs
trastuzumab deruxtecan
03
Conditions
solid neoplasmscancerMetastatic solid neoplasm
Beyond the preview
Go deeper on 2024-516158-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516158-22-00.